REVTx-99 is under clinical development by Revelation Biosciences and currently in Phase I for Allergic Rhinitis. According to GlobalData, Phase I drugs for Allergic Rhinitis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how REVTx-99’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
REVTx-99 is under development for the treatment of patients with chronic nasal congestion without polyps, allergic rhinitis to rye grass pollen, coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus type including A (H1N1 or H5N1) and B, parainfluenza and respiratory syncytial virus (RSV) infections. The drug candidate is an intranasal formulation of phosphorylated hexaacylated disaccharide .administered in the form of drops. It acts by targeting toll like receptor 4 (TLR4).
The drug candidate was under development for the treatment of H3N2 influenza (influenza A).
Revelation Biosciences overview
Revelation Biosciences is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company is headquartered in San Diego, California, the US.
For a complete picture of REVTx-99’s drug-specific PTSR and LoA scores, buy the report here.